HIV Mutation Detail Information

Virus Mutation HIV Mutation K103N


Basic Characteristics of Mutations
Mutation Site K103N
Mutation Site Sentence Among 12 patients with viral load 400–999 copies/mL, 4 (33·3%) had  ≥ 1 RAM, most commonly M184V/I and K103N/S (Table 8).
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region RT
Standardized Encoding Gene gag-pol:155348
Genotype/Subtype HIV-1
Viral Reference -
Functional Impact and Mechanisms
Disease HIV Infections    
Immune -
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information Y
Treatment NNRTIs
Location Ghana
Literature Information
PMID 31922120
Title Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa
Author Villa G,Abdullahi A,Owusu D,Smith C,Azumah M,Sayeed L,Austin H,Awuah D,Beloukas A,Chadwick D,Phillips R,Geretti AM
Journal EClinicalMedicine
Journal Info 2020 Jan 5;18:100231
Abstract BACKGROUND: This prospective pilot study explored same-day point-of-care viral load testing in a setting in Ghana that has yet to implement virological monitoring of antiretroviral therapy (ART). METHODS: Consecutive patients accessing outpatient care while on ART underwent HIV-1 RNA quantification by Xpert. Those with viraemia at the first measurement (T0) received immediate adherence counselling and were reassessed 8 weeks later (T1). Predictors of virological status were determined by logistic regression analysis. Drug resistance-associated mutations (RAMs) were detected by Sanger sequencing. FINDINGS: At T0, participants had received treatment for a median of 8.9 years; 297/333 (89.2%) were on NNRTI-based ART. The viral load was >/=40 copies/mL in 164/333 (49.2%) patients and >/=1000 copies/mL in 71/333 (21.3%). In the latter group, 50/65 (76.9%) and 55/65 (84.6%) harboured NRTI and NNRTI RAMs, respectively, and 27/65 (41.5%) had >/=1 tenofovir RAM. Among 150/164 (91.5%) viraemic patients that reattended at T1, 32/150 (21.3%) showed resuppression <40 copies/mL, comprising 1/65 (1.5%) subjects with T0 viral load >/=1000 copies/mL and 31/85 (36.5%) subjects with lower levels. A T0 viral load >/=1000 copies/mL and detection of RAMs predicted ongoing T1 viraemia independently of self-reported adherence levels. Among participants with T0 viral load >/=1000 copies/mL, 23/65 (35.4%) showed resuppression <1000 copies/mL; the response was more likely among those with higher adherence levels and no RAMs. INTERPRETATION: Same-day point-of-care viral load testing was feasible and revealed poor virological control and suboptimal resuppression rates despite adherence counselling. Controlled studies should determine optimal triaging modalities for same-day versus deferred viral load testing. FUNDING: University of Liverpool, South Tees Infectious Diseases Research Fund.
Sequence Data -
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.